Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
Authors' conclusion
Among Dutch T2D patients who were GLP-1ra naïve and initiated oral semaglutide, significant reductions in HbA1c and body weight were observed over 12 months, consistent with prospective clinical trial data. These results provide a first-look insight into real-world glycaemic control and body weight reduction in early adopters of oral semaglutide in the Netherlands.
Study context
- Population
- GLP-1 RA-naïve T2D patients initiating oral semaglutide 1 Jan 2020–31 Dec 2022, the Netherlands; mean (SD) age 62 (11) years, baseline HbA1c 70 (14) mmol/mol, body weight 102 (19) kgGLP-1 RA naïve of 932
- Participants
- 731 patients
- Outcome
- Change from baseline in HbA1c, body weight, blood lipids and blood pressure
- Follow-up
- 12 months
Methodological detailsobservational, real-world, PHARMO Data Network
- Observational
- Real-world
- PHARMO Data Network
Main finding
As reported in the abstract
Change in HbA1c from baseline
Oral semaglutide
−16.05
mean · 95% CI −12.57–-19.54 · mmol/mol
- Achieved personalized HbA1c targets
- 70%
Observational data: associations, not effects.
Further findings
Change in body weight from baseline · 12 months
- Body weight change from baseline
- mean −4.73 (−3.63, −5.83) kg (95% CI)
- 260 patients; average follow-up 8.2 months
Blood lipids and blood pressure
- Minimal changes in blood lipid parameters and diastolic BP; moderate changes in systolic BP
Original publication
Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network. Diabetes Obes Metab. Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →